Abstract
Dihydropyridines (DHPs), as exemplified by nifedipine (Vater et al. 1972), have become known as very powerful calcium antagonists and are important drugs in cardiovascular medicine. The discovery of DHPs with an agonistic action at the calcium channel opposite to that of the clinically widely used calcium antagonists has greatly enhanced our understanding how the calcium channel works (see Bechem et al. 1988). The prototype of these so-called calcium agonists, BAY K 8644 (Schramm et al. 1983), has been intensively investigated and proven to be a valuable pharmacological tool (Bechem et al. 1988). But none of the compounds reported on so far have been suitable for clinical use, mainly because they produce unacceptable vasoconstriction.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bechem M, Pieper F, Pott L (1985) Guinea-pig atrial cardioballs. Basic Res Cardiol 80 [Suppl]: 19–22
Bechem M, Hebisch S, Schramm M (1988) Ca-agonists: new sensitive probes for Cachannels. Trends Pharmacol Sci 9:257–261
Erne P, Bürgisser E, Bühler FR, Dubach B, Kühnis H, Meier M, Rogg H (1984) Enhancement of calcium influx in human platelets by CGP 28-392, a novel dihydropyridine. Biochem Biophys Res Commun 118:842–847
Franckowiak G, Bechem M, Schramm M, Thomas G (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on the Ca-channels. Eur J Pharmacol 114:223–226
Gross R, Bechem M, Kayser M, Schramm M, Taniel R, Thomas G (1985a) Effects of the Ca-agonistic dihydropyridine BAY K 8644 on the heart. In: Fleckenstein A, van Breemen C, Gross R, Hoffmeister F (eds) Cardiovascular effects of dihydropyridine-type calcium antagonists and agonists. Springer, Berlin Heidelberg New York, pp 218–232
Gross R, Kayser M, Schramm M, Taniel R, Thomas G (1985b) Cardiovascular effects of the Ca-agonistic dihydropyridine BAY K 8644 in conscious dogs. Arch Intern Pharmacodyn Ther 277:203–216
Gross R, Bechem M, Hebisch S, Schramm M (1990) Ca-Agonists. In: Abraham S, Amitai G (eds) Calcium channel modulators in heart and scmooth muscle: basic mechanisms and pharmacological aspects. VCH Weinheim/Deerfield Beach Balaban, Rehovot/Philadelphia, pp 353–365
Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane pathches. Pflugers Arch 391:85–100
Hof RP, Rüegg UT, Hof A, Vogel A (1985) Stereoselectivity at the calcium channel: opposite action of the enantiomers of a 1,4-dihydropyridine. J Cardiovasc Pharmacol 7:689–693
Hwang KS, van Breemen C (1985) Effects of the agonist BAY K 8644 on 45Ca-influx and net Ca-uptake into rabbit smooth muscle. Eur J Pharmacol 116:299–305
Janis RA, Rampe D, Sarmiento JG, Triggle DJ (1984) Specific binding of the Cachannel activator BAY K 8644 to membranes from cardiac muscle and brain. Biochem Biophys Res Commun 121:317–323
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe conjestive heart failure. N Engl J Med 325:1468–1475
Sanguinetti MC, Kass RS (1984) Regulation of cardiac calcium channel current and contractile activity by the dihydropyridine BAY K 8644 is voltage-dependent. J Mol Cell Cardiol 16:667–670
Schramm M, Thomas G, Towart R, Franckowiak G (1983) Novel dihydropyridines with positive inotropic action through activation of Ca-channels. Nature 203: 535–537
Schramm M, Towart R, Lamp B, Thomas G (1985) Modulation of calcium ion influx by the 1,4-dihydropyridines nifedipine and BAY K 8644. J Cardiovasc Pharmacol 7:493–496
Siess M, Stieler K, Seifart HJ (1981) Zur Wirkung von ARL-115 BS auf Funktion und Sauerstoffverbrauch isolierter Meerschweinchenherzvorhofe im Vergleich zu g-Strophantin und Theophyllin. Arzneimittelforschung 31:165–170
Thomas G, Gross R, Schramm M (1984) Calcium channel modulation: ability to inhibit or promote calcium influx resides in the same dihydropyridine molecule. J Cardiovasc Pharmacol 6:1170–1176
Uretsky BF, Jessupo M, Konstam MA, Sandberg A, for the Enoximone multicenter trial group (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82:774–780
Vater W, Kroneberg G, Hoffmeister F, Kaller H, Meng K, Oberdorf A, Puls W, Schloßmann K, Stoepel K (1972) Zur Pharmakologie von 4-(2'Nitrophenyl)-2,6dimethyl-l,4-dihydropyridin-3,5-dicarbon-säuredimethylester (Nifedipin, BAY A 1040). Arzneimittelforschung 22:1–14
Xamoterol In Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336:1–6
Yusuf S, Teo K (1990) Inotropic agents increase mortality in patients with congestive heart failure. Circulation 82 [Suppl]:673
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gross, R., Bechem, M., Hebisch, S., Hütter, J., Rounding, P., Schramm, M. (1993). Calcium Agonists. In: Busse, WD., Garthoff, B., Seuter, F. (eds) Dihydropyridines. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-95716-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-95716-1_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-57308-1
Online ISBN: 978-3-642-95716-1
eBook Packages: Springer Book Archive